Introduction Many individuals with major depressive disorder (MDD) do not respond to initial
antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non …

Background Non-response to first-line treatment for major depressive disorder (MDD) is
common; for such individuals, quality of life (QoL) impairments can be severe. Identifying …

Objective: To evaluate the effect of adjunctive aripiprazole to antidepressant therapy (ADT)
on functional outcomes, as assessed by the Sheehan Disability Scale (SDS). Method: A post …

Objective: To report the symptomatic and functional outcomes in patients with major
depressive disorder (MDD) during a 2-phase treatment trial and to estimate the value of …

Functional impairments are a common concern for individuals with major depressive
disorder (MDD) that does not resolve with initial antidepressant treatment. Such concerns …

Background Cognitive deficits are detectable in major depressive disorder (MDD). The
cognitive impact of antidepressants remains unclear, as does the cognitive effects of …

Introduction: Effective management of major depressive disorder (MDD) continues to be a
challenging task for psychiatrists and primary care physicians. This trial evaluated the …

Objectives To explore the effect of escitalopram combined with aripiprazole on cognitive
function in patients with major depressive disorder (MDD), and to evaluate the clinical …

Personalizing treatment for late-life depression requires identifying and integrating
information from multiple factors that influence treatment efficacy (moderators). We …

Objective To report side effect frequency and severity in patients with major depressive
disorder (MDD) receiving escitalopram and aripiprazole adjunctive therapy and to examine …